Live Breaking News & Updates on Carla Vozone

Stay updated with breaking news from Carla vozone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease asso


CET
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease asso
CORK, Ireland, March 17, 2021 /PRNewswire/ Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in the United States and tested 2 different strengths of minocycline against vehicle in a 1:1:1 randomization. This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®. ....

United States , New Jersey , George Magrath , Prnewswire Hovione , Carla Vozone , Contactisabel Pina , Courtney Smith , Contract Development , Communications Tel , Business Development Licensing , Lexitas Pharma Services , Manufacturing Organization , Ophthalmology Innovation Summit , Dry Eye Showcase , Dry Eye , Meibomian Gland Dysfunction , Visual Analogue Scale , Cornea Fluorescein Staining , Vice President , Clinical Perspectives , Dry Eye Disease , Minocycline Ophthalmic , Business Development , Isabel Pina , Director External Communications , ஒன்றுபட்டது மாநிலங்களில் ,

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction


Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
News provided by
Share this article
Share this article
CORK, Ireland, March 17, 2021 /PRNewswire/  Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in the United States and tested 2 different strengths of minocycline against vehicle in a 1:1:1 randomization. This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®. ....

United States , New Jersey , Isabel Pina , George Magrath , Carla Vozone , Courtney Smith , Contract Development , Business Development Licensing , Lexitas Pharma Services , Manufacturing Organization , Ophthalmology Innovation Summit , Dry Eye Showcase , Dry Eye , Meibomian Gland Dysfunction , Visual Analogue Scale , Cornea Fluorescein Staining , Vice President , Clinical Perspectives , Dry Eye Disease , Minocycline Ophthalmic , Business Development , Director External Communications , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜெர்சி , இசபெல் பினா , ஜார்ஜ் மக்ரத் ,